Compare · IMMU vs ORKA
IMMU vs ORKA
Side-by-side comparison of Immunomedics, Inc. (IMMU) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMMU and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA carries a market cap of $3.63B.
- ORKA has hit the wire 11 times in the past 4 weeks while IMMU has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for IMMU).
- Company
- Immunomedics, Inc.
- Oruka Therapeutics Inc.
- Price
- -
- $60.12-3.49%
- Market cap
- -
- $3.63B
- 1M return
- -
- -13.81%
- 1Y return
- -
- +378.24%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
Latest IMMU
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- NorthStar Appoints Peter Pfreundschuh to Board of Managers
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- FDA Approval for TRODELVY issued to IMMUNOMEDICS INC
- SEC Form SC 13G/A filed
- Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer
- Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)